Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2

Diagonal Bio
Download the release

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company"), with the point-of-care system LAMPlify®, announces the expansion of its equine testing panel to include the detection of Equine Herpesvirus type 2 (EHV-2). This enhancement broadens the Company’s product portfolio and addresses an unmet need in equine health. The addition of EHV-2 not only increases the utility of LAMPlify but also opens up significant new opportunities in the global equine diagnostics market.

On 18 September 2025, Diagonal Bio announced that Stall Courant had placed an order for LAMPLify, following a successful pilot study. In connection with the pilot study, and in close collaboration with Stall Courant, Diagonal Bio has developed and validated a new test for EHV-2. This virus is common and linked to respiratory symptoms and skin disease in horses. Early and reliable detection is important for veterinarians and trainers to manage health risks, improve treatment decisions, and protect both individual horses and larger stables from potential outbreaks.

“By expanding our diagnostic test panel to include Equine Herpesvirus type 2, we are strengthening our offering in equine diagnostics. The demand for reliable and rapid testing continues to grow, and this addition allows us to address an even broader segment of the market. It is an important step in building a comprehensive portfolio for equine diseases while creating added value for our customers.” - Karin Wehlin, CEO of Diagonal Bio AB (publ)

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.

Attachments
Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.